Oncternal Therapeutics to Present Q1 2024 Business Update and Financial Results

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Diego, and listed on the Nasdaq stock exchange under the ticker symbol ONCT, has announced plans to release its financial results for the first quarter of 2024. The announcement will be made after the close of U.S. financial markets on Thursday, May 9, 2024. To discuss the financial results and provide a business update, the company's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET). This webcast will be accessible online at the company's investor relations website and will be archived there for at least 30 days.

Oncternal Therapeutics specializes in developing innovative cancer therapies, targeting critical unmet medical needs in oncology. The company's research focuses on exploiting novel biological pathways that contribute to cancer progression, with a particular emphasis on hematological malignancies and prostate cancer.

One of Oncternal's leading investigational treatments is ONCT-534, a dual-action androgen receptor inhibitor (DAARI). This drug has shown preclinical efficacy in prostate cancer models, targeting both unmutated androgen receptors (AR) and various aberrant forms. ONCT-534 aims to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who have developed resistance to existing androgen receptor pathway inhibitors. This includes patients with AR gene amplifications, mutations in the AR ligand binding domain (LBD), or splice variants lacking the AR LBD. The clinical trial, ONCT-534-101 (NCT05917470), has successfully completed enrollment in three dosage cohorts and continues to recruit and treat mCRPC patients.

Another key investigational therapy from Oncternal is ONCT-808, an autologous chimeric antigen receptor T (CAR T) cell therapy. This treatment targets the Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using a binding domain derived from zilovertamab. Preclinical studies have demonstrated ONCT-808's effectiveness against various hematological malignancies and solid tumors, with specificity for cancer cells expressing ROR1. Oncternal has optimized a manufacturing process that potentially reduces the wait time for patients needing their personalized CAR T therapy, compared to existing CAR T products. The clinical trial, ONCT-808-101 (NCT05588440), involves patients with relapsed or refractory aggressive B-cell lymphoma, including those who have not responded to previous CD19 CAR T treatments.

Zilovertamab, another promising candidate from Oncternal, is an investigational monoclonal antibody designed to inhibit ROR1. In a Phase 1/2 study (CIRM-0001, NCT03088878), zilovertamab was tested in combination with ibrutinib for treating mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and marginal zone lymphoma (MZL). The study showed remarkable results, including a 100% progression-free survival rate at 42 months for CLL patients with p53 mutations or the del(17p) deletion—a group with limited treatment options. Furthermore, zilovertamab is being assessed in a Phase 1b study in combination with docetaxel for metastatic castration-resistant prostate cancer (NCT05156905).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!